BRIEF published on 03/21/2026 at 10:10, 8 days 15 hours ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
BRIEF published on 03/21/2026 at 10:10, 8 days 15 hours ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 8 days 15 hours ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 8 days 15 hours ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 2 months 17 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 01/12/2026 at 07:35, 2 months 17 days ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
PRESS RELEASE published on 01/12/2026 at 07:30, 2 months 17 days ago Informations privilégiées / Autres communiqués Aelis Farma reçoit l'avis favorable du Comité Pédiatrique de l'EMA sur le Plan d'Investigation Pédiatrique de AEF0217 dans la trisomie 21, renforçant la crédibilité du programme et sécurisant les exigences réglementaires EMA Aelis Farma Trisomie 21 AEF0217 Comité Pédiatrique
BRIEF published on 12/02/2025 at 07:05, 3 months 27 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 12/02/2025 at 07:05, 3 months 27 days ago Aelis Farma lance un essai clinique de Phase 2B pour AEF0217 chez les personnes avec trisomie 21 Essai Clinique Aelis Farma CB1-SSi Trisomie 21 AEF0217
PRESS RELEASE published on 12/02/2025 at 07:00, 3 months 27 days ago Informations privilégiées / Autres communiqués Aelis Farma obtient les autorisations pour l'essai de Phase 2B avec AEF0217 chez des personnes avec une trisomie 21, offrant un potentiel traitement novateur des troubles adaptatifs et cognitifs, comblant un besoin médical majeur Aelis Farma Essai De Phase 2b CB1-SSi Trisomie 21 AEF0217
Published on 03/29/2026 at 12:15, 13 hours 22 minutes ago China Xlx Announces 2025 Annual Results Deepening Efforts in Reducing Costs, Enhancing Efficiency, Strengthening Competitiveness Through Differentiation and Driving Marketing Transformation
Published on 03/28/2026 at 01:00, 2 days ago Battery X Metals Announces Confidential Submission of Amended Draft Registration Statement with the U.S. Securities and Exchange Commission in Connection with Proposed U.S. National Securities Exchange Initial Public Offering
Published on 03/28/2026 at 00:55, 2 days ago Notification of Relevant Change to Significant Shareholder
Published on 03/29/2026 at 17:05, 8 hours 32 minutes ago FAST III trial demonstrates non-inferiority of CAAS vFFR to invasive wire-based FFR
Published on 03/28/2026 at 10:05, 1 day 15 hours ago Hisense Advances a Quiet Green Revolution in Home Entertainment
Published on 03/28/2026 at 08:56, 1 day 16 hours ago Turkiye Garanti Bankasi A.S.: Sale of Garanti Bank S.A. and our public disclosure dated 10.03.2026
Published on 03/28/2026 at 01:42, 1 day 22 hours ago EQS-Adhoc: Raiffeisen Bank International AG: Agreement on the acquisition of Garanti BBVA Group Romania
Published on 03/27/2026 at 21:58, 2 days 3 hours ago Kaufman & Broad SA: Availability of the Universal Registration Document 2025
Published on 03/27/2026 at 19:06, 2 days 6 hours ago Mersen : Déclaration des transactions sur actions propres
Published on 03/27/2026 at 18:52, 2 days 6 hours ago Crédit Agricole CIB announces the publication of its 2025 Universal Registration Document
Published on 03/27/2026 at 18:52, 2 days 6 hours ago Crédit Agricole CIB annonce la publication de son Document d’enregistrement universel 2025
